- Conditions
- Sarcoma
- Interventions
- carboplatin, paclitaxel
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 73 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1369–1392
of 1,429
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
- Interventions
- Atezolizumab, Nab-paclitaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 955
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
- Drug
- Lead sponsor
- Pancreatic Cancer Action Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Endometrial Neoplasms
- Interventions
- Paclitaxel, Sapanisertib, MLN1117
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Greenbrae, California + 17 more
- Conditions
- Carcinoma
- Interventions
- Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, Treatment determined by physician
- Drug · Other
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 21
- States / cities
- Huntsville, Alabama • Fort Myers, Florida • Jacksonville, Florida + 18 more
- Conditions
- Esophageal Cancer
- Interventions
- cetuximab, cisplatin, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 173
- States / cities
- Tucson, Arizona • Auburn, California • Cameron Park, California + 140 more
- Conditions
- Breast Cancer
- Interventions
- Post-operative adjuvant therapy, neoadjuvant therapy, therapeutic surgical procedure, Radiation therapy with concurrent Paclitaxel, Hormonal Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 6
- States / cities
- Frankling, Tennessee • Jackson, Tennessee • Memphis, Tennessee + 1 more
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Tumors, Malignant Neoplasm of Breast
- Interventions
- Paclitaxel, Alisertib
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Including Dallas and Austin, Texas
- Conditions
- Breast Cancer
- Interventions
- Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin, Definitive Surgery, Radiotherapy
- Drug · Procedure · Radiation
- Lead sponsor
- Leo W. Jenkins Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
- Interventions
- CS-1008, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Oklahoma City, Oklahoma
- Conditions
- Breast Cancer
- Interventions
- Nivolumab 360mg, Paclitaxel 80mg/m^2, Doxorubicin 60mg/m^2, Cyclophosphamide 600mg/m^2, Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2, Trastuzumab 8mg/kg and 6 mg/kg, Pertuzumab 840mg and 420mg
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Bloomington, Indiana • New York, New York
- Conditions
- Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Resectable Non-small Cell Lung Cancer
- Interventions
- Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Clermont, Florida • Chicago, Illinois • Westwood, Kansas + 5 more
- Conditions
- Head and Neck Cancer
- Interventions
- gemcitabine, paclitaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 123
- States / cities
- Anniston, Alabama • Mobile, Alabama • Aurora, Colorado + 81 more
- Conditions
- Invasive Breast Cancer
- Interventions
- doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, lapatinib
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 103
- States / cities
- Mobile, Alabama • La Jolla, California • Long Beach, California + 88 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- vorinostat, paclitaxel, carboplatin, placebo, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Advanced Breast Cancer, Advanced Malignant Solid Tumors, Breast Neoplasms
- Interventions
- HKI-272, Paclitaxel
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 8
- States / cities
- La Jolla, California • San Diego, California • Boston, Massachusetts + 4 more
- Conditions
- Supportive, Ill-defined Sites
- Interventions
- paclitaxel, docetaxel, taxane, taxane
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Breast Cancer
- Interventions
- Panitumumab, Nab-paclitaxel, Carboplatin, 5-Fluorouracil, Epirubicin, Cyclophosphamide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer
- Interventions
- Sorafenib, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 17
- States / cities
- Jonesboro, Arkansas • Fort Lauderdale, Florida • Fort Myers, Florida + 13 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, Abraxane, FOLFIRINOX, Chemoradiation
- Drug · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HER2-positive Breast Cancer
- Interventions
- HER-2 pulsed DC1, Trastuzumab, Pertuzumab, Paclitaxel, Resection surgery
- Biological · Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Breast Adenocarcinoma, Inflammatory Breast Carcinoma
- Interventions
- pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Lancaster, California • South Pasadena, California